PMID: 8961125Sep 1, 1996Paper

A population based strategy to prevent insulin-dependent diabetes using nicotinamide

Journal of Pediatric Endocrinology & Metabolism : JPEM
R B ElliottA W Stewart

Abstract

It has been postulated that treatment with nicotinamide may prevent or delay the onset of insulin dependent diabetes mellitus. We report the findings of a population based diabetes prevention trial which tests this hypothesis. 33,658 school children aged 5-7.9 years were randomly selected (by school) from a total population of 81,993 of such children in the Auckland (New Zealand) region. They were offered testing for islet cell antibodies. 20,195 (60%) consented to testing. Of these 185 had islet cell antibodies and met the criteria for treatment with nicotinamide. 173 received this treatment. The study population has an average follow up time of 7.1 years. The diabetes incidence of the untested controls was: 16.07 (12.4-20.5 95% CI) /100,000 person years at risk; in the group who were tested and treated when deemed appropriate: 7.14 (3.1-14.1 95% CI); and in the group offered testing but who did not consent ("refusers'): 18.48 (10.1-31.0 95% CI). The tested group had a rate of diabetes of 41% (20-85 95% CI) of the other groups combined after an age adjustment, which is significant (p = 0.008). The tested group combined with the "refuser' group (i.e. "intention to treat') also has a lower incidence than the control group (p = 0...Continue Reading

References

Dec 1, 1977·The American Journal of Clinical Nutrition·O Pelletier, R Brassard
Oct 1, 1992·Diabetes Care·P J BingleyE A Gale
May 8, 1990·Journal of Immunological Methods·C C Pilcher, R B Elliott
Jan 1, 1995·Clinical Pharmacology and Therapeutics·L B Sheiner, D B Rubin
Dec 1, 1994·Journal of Autoimmunity·R B Elliott, C C Pilcher

❮ Previous
Next ❯

Citations

Jul 31, 1998·European Journal of Pharmacology·C Szabó
Jun 6, 2000·Advanced Drug Delivery Reviews·P M Graves, G S Eisenbarth
Mar 27, 2004·Lancet·E A M GaleUNKNOWN European Nicotinamide Diabetes Intervention Trial (ENDIT) Group
Jul 23, 2014·Trends in Immunology·Jorg van Loosdregt, Paul J Coffer
Nov 23, 2005·Pediatric Clinics of North America·Anna CasuMassimo Pietropaolo
Jul 3, 2002·Endocrinology and Metabolism Clinics of North America·Peter A Gottlieb, Anthony R Hayward
Apr 1, 2004·Endocrinology and Metabolism Clinics of North America·Francesco Vendrame, Peter A Gottlieb
Nov 18, 2014·Journal of Cosmetic Dermatology·Heidi M Rolfe
Aug 22, 2016·Current Opinion in Immunology·Anne M PesenackerMegan K Levings
Sep 14, 2016·Journal of Pharmacy Practice·Zera YilmazNissa Mazzola
Jul 9, 2002·The British Journal of Dermatology·T HakozakiR E Boissy
Mar 10, 2001·Antioxidants & Redox Signaling·C M PayneH Garewal
Dec 17, 2005·Antioxidants & Redox Signaling·Andrea M VincentEva L Feldman
Apr 18, 2001·Diabetes/metabolism Research and Reviews·J LudvigssonL Stenhammar
Mar 4, 2005·Treatments in Endocrinology·Dominique Bonnefont-Rousselot
Jan 7, 2006·International Journal of Epidemiology·Debbie A Lawlor, Nish Chaturvedi
Mar 10, 1999·Brain : a Journal of Neurology·S LoveG K Wilcock
Oct 7, 2019·Metabolomics : Official Journal of the Metabolomic Society·Seon Beom SongEun Seong Hwang
Aug 24, 2001·Journal of Pediatric Endocrinology & Metabolism : JPEM·Z Laron
Nov 20, 1998·Acta Paediatrica. Supplement·M Knip
Jan 8, 2004·Annals of Medicine·Arno HänninenChristian Kurts
May 6, 2020·Biomolecules·Eun Seong Hwang, Seon Beom Song
Aug 5, 1999·Autoimmunity·G FlandersM Rewers
Aug 28, 2020·Canadian Journal of Physiology and Pharmacology·Natália Cristina Gomes Carvalho LimaMaria Esméria Corezola do Amaral

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.